ARTICLE | Emerging Company Profile
Yeast on the brain
How Yumanity's platforms allow it to uncover novel neurology targets
April 25, 2016 7:00 AM UTC
Yumanity Therapeutics LLC is using an iterative loop of phenotypic screens to tackle diseases caused by misfolded proteins. The company, led by veteran biotech executive Tony Coles and backed by investors with long-term horizons, is focused on Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
Coles founded Yumanity in 2014 along with Susan Lindquist. Coles was chairman, president and CEO of Onyx Pharmaceuticals Inc., which Amgen Inc. acquired for $10.4 billion in 2013. ...